NF-κB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of hepatocellular adenoma by Köhler, Ulrike A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
NF-￿B/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to
prevent development of hepatocellular adenoma
Köhler, Ulrike A; Böhm, Friederike; Rolfs, Frank; Egger, Michèle; Hornemann, Thorsten; Pasparakis,
Manolis; Weber, Achim; Werner, Sabine
Abstract: BACKGROUND AND AIMS: The liver is frequently challenged by toxins and reactive oxygen
species. Therefore, hepatocytes require cytoprotective strategies to cope with these insults. Since the
transcription factors Nrf2 and NF-￿B regulate the cellular antioxidant defense system and important sur-
vival pathways, we determined their individual and overlapping functions in the liver. METHODS: We
generated mice lacking Nrf2 and the NF-￿B RelA/p65 subunit in hepatocytes and we analyzed their liver
using histopathology, immunohistochemistry, quantitative RT-PCR, Westernblot and Oxyblot analysis.
Human inflammatory hepatocellular adenomas (iHCA) were analyzed by immunohistochemistry. RE-
SULTS: Loss of either Nrf2 or NF-￿B/RelA had only a minor effect on liver homeostasis, but the double
knockout mice spontaneously developed liver inflammation and fibrosis. Upon aging, more than one third
of the female double mutant mice developed tumors, which histologically resemble human iHCA, a tumor
that predominantly occurs in women. The mouse tumors also recapitulated the immunohistochemical
marker profile characteristic for human iHCA. Moreover, pNRF2 and NF-￿B RelA/p65 was not detectable
in the nuclei of iHCA tumor cells. The mouse phenotype was not due to a synergistic effect of both tran-
scription factors on cytoprotective Nrf2 target genes. Rather, loss of Nrf2 or NF-￿B/RelA altered the
expression of different genes, and the combination of these alterations likely affects liver homeostasis in
the double mutant mice. CONCLUSIONS: Our results provide genetic evidence for a functional cross-
talk of Nrf2 and NF-￿B/RelA in hepatocytes, which protects the liver from necrosis, inflammation and
fibrosis. Furthermore, the double mutant mice represent a valuable animal model for iHCA.
DOI: 10.1016/j.jhep.2015.08.033
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-113449
Accepted Version
 
 
Originally published at:
Köhler, Ulrike A; Böhm, Friederike; Rolfs, Frank; Egger, Michèle; Hornemann, Thorsten; Pasparakis,
Manolis; Weber, Achim; Werner, Sabine (2016). NF-￿B/RelA and Nrf2 cooperate to maintain hepatocyte
integrity and to prevent development of hepatocellular adenoma. Journal of Hepatology, 64(1):94-102.
DOI: 10.1016/j.jhep.2015.08.033
Accepted Manuscript
NF-κB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent
development of hepatocellular adenoma
Ulrike A. Köhler, Friederike Böhm, Frank Rolfs, Michèle Egger, Thorsten
Hornemann, Manolis Pasparakis, Achim Weber, Sabine Werner
PII: S0168-8278(15)00613-3
DOI: http://dx.doi.org/10.1016/j.jhep.2015.08.033
Reference: JHEPAT 5820
To appear in: Journal of Hepatology
Received Date: 21 January 2015
Revised Date: 12 August 2015
Accepted Date: 31 August 2015
Please cite this article as: Köhler, U.A., Böhm, F., Rolfs, F., Egger, M., Hornemann, T., Pasparakis, M., Weber, A.,
Werner, S., NF-κB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of
hepatocellular adenoma, Journal of Hepatology (2015), doi: http://dx.doi.org/10.1016/j.jhep.2015.08.033
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
  Köhler et al. 
 1 
 
NF-κB/RelA and Nrf2 cooperate to maintain hepatocyte 
integrity and to prevent development of hepatocellular 
adenoma 
 
Ulrike A. Köhler1, Friederike Böhm2, Frank Rolfs1, Michèle Egger2, 
Thorsten Hornemann3, Manolis Pasparakis4, Achim Weber2* and 
Sabine Werner1* 
 
1Department of Biology, Institute of Molecular Health Sciences, Swiss Federal 
Institute of Technology (ETH) Zurich, 8093 Zurich, Switzerland 
2Institute of Surgical Pathology, and 3Institute of Clinical Chemistry, University of 
Zurich and University Hospital Zurich, 8091 Zurich, Switzerland 
4Institute for Genetics, University of Cologne, 50674 Cologne, Germany 
 
*Address for correspondence (joint corresponding and senior authors): 
Prof. Dr. Sabine Werner, Institute of Molecular Health Sciences, Otto-Stern-Weg 
7, 8093 Zurich, Switzerland, Tel.: +41 44 633 3941; Fax: +41 44 633 1174, E-
mail: Sabine.werner@biol.ethz.ch  
Prof. Dr. Achim Weber, Institute of Surgical Pathology, University of Zurich and 
University Hospital of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland, 
Tel.: 41 44 255 2781; E-mail: achim.weber@usz.ch 
Electronic word count: 250 (abstract); 6294 (total) 
Number of Figures: 7; number of Tables: 0
  
  Köhler et al. 
 2 
List of abbreviations 
ALT: alanine transaminase 
ARE: Antioxidant response element 
AST: aspartate transaminase 
BHA: Butylated hydroxyanisole 
BrdU: 5-bromo-2’-deoxyuridine  
FABP: Fatty acid binding protein 
Gclc: Glutamate-cysteine ligase catalytic subunit 
Gsta2: Glutathione S-transferase 2 
Hmox1: Heme oxygenase 1 
iHCA: Inflammatory hepatocellular adenoma 
NADPH: Nicotinamide adenine dinucleotide phosphate 
NF-κB: Nuclear factor κB 
Nqo1: NADP(H) dehydrogenase, quinone 1 
Nrf2: Nuclear factor erythroid 2-related factor 2  
PBS: Phosphate-buffered saline 
Prdx: Peroxiredoxin 
ROS: Reactive oxygen species 
  
  Köhler et al. 
 3 
SAA1: Serum amyloid A1 
STAT3: Signal transducer and activator of transcription 3  
TNF-α: Tumor necrosis factor α 
 
Key words: Nrf2, NF-κB, hepatocellular adenoma, inflammation, liver fibrosis 
Conflict of interest: None 
Financial support: Supported by grants from ETH Zurich (No. 0-23123-08 to 
S.W.), the Swiss National Science Foundation (310030-142884 to S.W.), the 
Swiss Cancer League (KLS – 02773-02-2011 to A.W.), the Promedica 
Foundation Chur (to A.W.), and the Boehringer Ingelheim Fonds (predoctoral 
fellowship to U.A.K). U.A.K. was a member of the International Research 
Training Group (IRTG 1331; Konstanz/Zürich). 
Authors’ contributions: U.A.K, F.B., F.R., M.E. and T.H. performed the 
experiments, M.P. provided p65 knockout mice and initiated the study together 
with S.W., A.W. performed the histopathological analysis and coordinated the 
study together with S.W. S.W. wrote the manuscript together with U.A.K. and 
designed the study. All authors made important comments to the manuscript.  
  
  
  Köhler et al. 
 4 
Abstract 
Background and Aims: The liver is frequently challenged by toxins and reactive 
oxygen species. Therefore, hepatocytes require cytoprotective strategies to cope 
with these insults. Since the transcription factors Nrf2 and NF-κB regulate the 
cellular antioxidant defense system and important survival pathways, we 
determined their individual and overlapping functions in the liver. 
Methods: We generated mice lacking Nrf2 and the NF-κB RelA/p65 subunit in 
hepatocytes and we analyzed their liver using histopathology, 
immunohistochemistry, quantitative RT-PCR, Westernblot and Oxyblot analysis. 
Human inflammatory hepatocellular adenomas (iHCA) were analyzed by 
immunohistochemistry. 
Results: Loss of either Nrf2 or NF-κB/RelA had only a minor effect on liver 
homeostasis, but the double knockout mice spontaneously developed liver 
inflammation and fibrosis. Upon aging, more than one third of the female double 
mutant mice developed tumors, which histologically resemble human iHCA, a 
tumor that predominantly occurs in women. The mouse tumors also recapitulated 
the immunohistochemical marker profile characteristic for human iHCA. 
Moreover, pNRF2 and NF-κB RelA/p65 was not detectable in the nuclei of iHCA 
tumor cells. The mouse phenotype was not due to a synergistic effect of both 
transcription factors on cytoprotective Nrf2 target genes. Rather, loss of Nrf2 or 
NF-κB/RelA altered the expression of different genes, and the combination of 
these alterations likely affects liver homeostasis in the double mutant mice.  
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Conclusions: Our results provide genetic evidence for a functional cross-talk of 
Nrf2 and NF-κB/RelA in hepatocytes, which protects the liver from necrosis, 
inflammation and fibrosis. Furthermore, the double mutant mice represent a 
valuable animal model for iHCA. 
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Introduction 
The liver’s capability to regenerate completely after tissue loss induced by 
viruses, toxins or surgery is unique and astounding. Chronic liver damage, which 
occurs for example upon long-term alcohol abuse or viral hepatitis, however, 
limits the regenerative potential drastically. This may lead to the development of 
liver fibrosis, cirrhosis, and finally tumorigenesis and/or liver failure. It has been 
suggested that oxidative stress plays a central role in impaired liver regeneration 
and liver tumorigenesis [1-3]. Therefore, further understanding of the 
mechanisms controlling redox homeostasis in the liver may contribute to the 
development of new strategies to prevent or treat chronic liver disease and 
ultimately liver cancer.  
A particularly important regulator of the cellular redox balance is nuclear factor 
erythroid 2-related factor 2 (Nrf2), a ubiquitously expressed member of the cap’n’ 
collar family of transcription factors. Nrf2 activity is controlled by binding to the 
cytoplasmic inhibitory protein Keap1, which also mediates its ubiquitination and 
subsequent proteasomal degradation. Oxidation or covalent modifications of 
cysteine residues in Keap1 weaken the interaction with Nrf2, allowing its 
stabilization and nuclear accumulation. In the nucleus, Nrf2 dimerizes with a 
small Maf protein, followed by binding to antioxidant response elements (AREs) 
in enhancer or promoter regions of genes encoding various antioxidant proteins 
and detoxifying enzymes [4]. The central role of Nrf2 in cytoprotection is 
demonstrated by the phenotype of Nrf2-deficient mice. Although young mice do 
not display obvious abnormalities, they were highly susceptible to different toxins, 
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and they showed enhanced susceptibility towards chemical carcinogenesis in 
various organs, including the liver [5,6]. 
We and others previously demonstrated the requirement of Nrf2 for liver 
regeneration. Nrf2-deficient mice displayed oxidative stress in the liver that was 
aggravated after liver injury. In addition, liver regeneration after partial 
hepatectomy was impaired in Nrf2 knockout mice as a result of partial 
insulin/insulin-like growth factor 1 resistance caused by oxidative stress and/or of 
impaired Notch signaling [7,8]. Nrf2-deficiency also caused impaired repair of 
carbon tetrachloride-induced liver damage and concomitant enhancement of the 
pro-inflammatory and pro-fibrotic response [9]. Interestingly, Nrf2 knockout mice 
displayed enhanced DNA binding of nuclear factor κB (NF-κB) after partial 
hepatectomy [7]. This is most likely the consequence of the oxidative stress in 
Nrf2-deficient cells, as ROS have been shown to activate NF-κB [10]. Since 
cytoprotective functions of NF-κB in hepatocytes have been demonstrated, in 
particular under stress conditions [11,12], we speculated that the increased 
activity of NF-κB in the regenerating liver of Nrf2 knockout mice could at least in 
part compensate for the loss of Nrf2. 
To test this possibility, we analyzed the consequences of a combined loss-of-
function of Nrf2 and NF-κB in hepatocytes. For this purpose we decided to use 
mice with a hepatocyte-specific loss of the NF-κB subunit p65/RelA [13]. The 
RelA/p65-p50 dimer is the most abundant NF-κB heterodimer in canonical NF-κB 
signaling, and it regulates various genes involved in the control of apoptosis and 
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inflammation [14]. Mice lacking p65/RelA in hepatocytes show a severe reduction 
in total NF-κB activity, but due to the presence of other NF-κB family members 
they do not exhibit a phenotype in the non-challenged liver. However, they are 
highly susceptible to lipopolysaccharide- and tumor necrosis factor (TNF)-α-
induced liver damage, respectively [13,15]. Interestingly, systemic treatment of 
these mice with the antioxidant butylated hydroxyanisole (BHA) prevented TNF-
α-induced apoptosis in p65/RelA deficient hepatocytes [15]. BHA had previously 
been shown to induce the expression of cytoprotective Nrf2 target genes, 
including NAD(P)H dehydrogenase, quinone 1 (Nqo1) and heme oxygenase 1 
(Hmox-1) as a consequence of direct Nrf2 activation [16,17]. This finding further 
suggests that Nrf2 and NF-κB have overlapping cytoprotective functions in the 
liver, and this hypothesis was experimentally confirmed in vivo in the present 
study. 
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Materials and Methods 
Mice. Nrf2 knockout mice [18] and mice homozygous for the floxed p65/RelA 
allele p65fl [13] were mated with homozygous Albumin-Cre (AlbCre) transgenic 
mice to obtain offspring heterozygous for Nrf2 or p65fl and hemizygous for 
AlbCre. These AlbCretg/wt_p65fl/wt and AlbCretg/wt_Nrf2ko/wt mice were then 
crossed to generate AlbCretg/wt_p65fl/fl or AlbCretg/tg_p65fl/fl and 
AlbCretg/wt_Nrf2ko/ko or AlbCretg/tg_Nrf2ko/ko mice, respectively. Finally, these lines 
were crossed to obtain AlbCretg/wt_p65wt/wt_ Nrf2wt/wt (here called AlbCre), 
AlbCretg/wt_p65fl/fl_ Nrf2wt/wt (here called AlbCre_p65ko), AlbCretg/wt_p65wt/wt_ 
Nrf2ko/ko (here called AlbCre_Nrf2ko), and AlbCretg/wt_p65fl/fl_ Nrf2ko/ko animals 
(here called AlbCre_p65ko/Nrf2ko). All mice were in C57BL/6 genetic 
background. 
Mice were housed and fed according to federal guidelines. They were free of 
pathogens. All animal experiments were performed with permission by the local 
veterinary authorities of Zurich, Switzerland.  
 
Preparation of liver tissue. After euthanization of mice by CO2 inhalation, blood 
was collected by cardiac puncture and liver tissue was harvested. For RNA 
isolation or preparation of protein lysates, liver samples were immediately frozen 
in liquid nitrogen and stored at -80 °C. For histology or immunohistochemistry 
liver samples were fixed in 4 % paraformaldehyde in phosphate-buffered saline 
(PBS) or in 95 % ethanol/1 % acetic acid and embedded in paraffin. 
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RNA isolation and quantitative RT-PCR (qRT-PCR). Isolation of RNA from 
murine liver was carried out as previously described [19]. cDNA synthesis was 
performed using the iScript RT kit (Biorad, Hercules, CA) according to the 
manufacturer’s instructions. qRT-PCR was performed as described previously 
[20] using the primers listed in Supplementary Materials. 
 
Preparation of protein lysates and Westernblot analysis. Liver samples were 
homogenized in T-PERTM tissue protein extraction reagent (Pierce, Rockford, IL) 
supplemented with 0.1 U/ml aprotinin, 1 % leupeptin, 1 % pepstatin, 1 mM 
AEBSF, 10 mM sodium pyrophosphate, 1 mM sodium vanadate and 50 mM 
sodium fluoride. Lysates were cleared by sonication and centrifugation. Protein 
concentrations were determined with the BCATM Protein Assay Kit (Pierce). 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes. Unspecific binding sites were blocked in 5 % milk in TBS-T (10 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 0.05 % Tween 20). Polyclonal antibodies against 
NF-κB/RelA (sc-372, Santa Cruz, Santa Cruz, CA) or GAPDH (#5G4, HyTest, 
Finland) were incubated in the blocking solution or in 5 % BSA/TBS-T at 4 °C 
overnight. Antibody-bound proteins were detected using a horseradish 
peroxidase-coupled secondary antibody (anti-rabbit-IgG; Promega, Madison, 
WI). 
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Oxyblot analysis. Protein lysates from total liver were analyzed using the 
Oxyblot technology as previously described [21]. Briefly, after derivatization with 
hydrazide-biotin (Pierce), proteins were acetone precipitated and afterwards 
dissolved in 100 mM NaOH. Carbonylated proteins were detected by 
Westernblot analysis using horseradish peroxidase-coupled streptavidin (R&D 
Systems; Minneapolis, MN). 
 
Histology and histomorphometry. Murine and routinely processed human liver 
samples were fixed in 4 % PFA in PBS overnight and embedded in paraffin. 
Analysis of human liver tissues was approved by the local ethics committee 
(“Kantonale Ethikkommission Zürich”, application number StV26/2005 and KEK-
ZH-Nr. 2013-0382). Sections (2 or 3.5 µm) were stained with hematoxylin/eosin 
(H&E) or Sirius Red (Sigma) and photographed (4 pictures/animal). Fibrotic 
tissue areas were manually determined using histomorphometry. 
 
Immunohistochemistry and immunofluorescence. Paraffin sections (2 or 
3.5 µm) from tissue that had been fixed in 4 % PFA or 95 % ethanol/1 % acetic 
acid were incubated for 45 min in 12 % BSA in PBS/0.025 % NP40/10 % NaN3 to 
block unspecific binding sites. Sections were incubated with the primary antibody 
diluted in blocking buffer overnight at 4 °C. After application of a secondary 
antibody for 1 h, they were stained using the Vectastain Peroxidase Kit  (Vector 
Laboratories, Burlingame, CA), counterstained with hematoxylin, rehydrated, and 
mounted with Mowiol. Alternatively, stainings were performed using a Ventana 
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staining platform (Roche, Rotkreuz, Switzerland). Sections were photographed 
using a Zeiss Imager.A1 microscope equipped with an Axiocam MRm camera 
and EC Plan-Neofluar objectives (10x/0.3, 20x/0.5). For data acquisition we used 
the Axiovision 4.6 software (all from Carl Zeiss, Inc., Oberkochen, Germany). 
Positive cells were quantified using the Image J software (Rasband WS, US NIH, 
Bethesda, MA). Antibodies used are listed in Supplementary Materials. 
 
Detection and quantification of proliferating or apoptotic cells. Mice were 
injected i.p. with 5-bromo-2’-deoxyuridine (BrdU) (250 mg/kg body weight) and 
sacrificed 2 h after injection. Liver tissue was fixed in 95 % EtOH/1 % acetic acid 
overnight. BrdU positive cells were detected using a peroxidase-coupled 
antibody directed against BrdU (Roche). Apoptotic cells were identified by 
TUNEL staining using the cell death detection kit (Roche). Stained sections were 
photographed (4 pictures/animal), and positive and negative cells were counted 
manually using the Image J software. 
 
Statistical analysis. Statistical analysis was performed using the GraphPad 
Prism5.0a software. p-values are two-tailed and were calculated using a regular 
Two-way ANOVA. Fisher’s exact test was used to calculate the significance of 
tumor formation in female versus male mice using QuickCalcs (GraphPad). P 
values < 0.05 were considered statistically significant.  
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Results 
Generation of mice lacking Nrf2 and p65/RelA in hepatocytes 
To unravel a possible cross-talk between Nrf2 and NF-κB signaling in the liver, 
we generated mice lacking Nrf2 in all cells and p65/RelA in hepatocytes. In the 
double mutant AlbCre_p65/Nrf2ko mice hepatocytes are deficient in both Nrf2 
and p65/RelA. qRT-PCR analysis verified the loss of Nrf2 and/or reduction in 
p65/RelA expression, respectively, in samples from total liver of the double or 
single knockout mice (Fig. 1A,B). The complete loss of Nrf2 in AlbCre_Nrf2ko 
and AlbCre_p65/Nrf2ko mice was confirmed by semiquantitative PCR (Fig. 1B, 
right panel). Westernblot analysis demonstrated a strong reduction in p65/RelA 
levels in AlbCre_p65 and AlbCre_p65/Nrf2ko mice (Fig. 1C). The residual p65 
expression occurs in non-parenchymal cells of the liver, including endothelial 
cells, as shown by immunofluorescence analysis (Fig. 1D). 
 
Simultaneous loss of Nrf2 and p65/RelA in hepatocytes induces spontaneous 
liver damage 
AlbCre_p65/Nrf2ko mice did not display obvious macroscopic abnormalities at 
the age of 8 weeks and they had a normal body weight (data not shown). As 
previously demonstrated [7], Nrf2 knockout mice had a significant reduction in the 
liver-to-body weight ratio. This phenotype was, however, not aggravated by 
additional loss of p65 (Fig. 2A). Analysis of serum activities for aspartate 
transaminase (AST) and alanine transaminase (ALT) indicated lack of liver 
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damage in single and double knockout mice (Fig. 2B and data not shown). The 
number of TUNEL-positive apoptotic cells was also not significantly altered (Fig. 
2C). Histological analysis of H&E stained liver sections showed that the overall 
liver morphology was not affected. However, focal accumulation of inflammatory 
cells was seen in the liver of AlbCre_p65ko mice and even more in 
AlbCre_p65/Nrf2ko mice (Fig. 2D, right picture in lower panel). In most cases this 
was accompanied by necrosis in the immediate environment (data not shown). 
Immunohistochemical analysis of liver sections showed a slight, but non-
significant increase in the number Ly6G-positive neutrophils and of CD3-positive 
T cells in AlbCre_p65/Nrf2ko mice compared to controls (Fig. 2E). 
 
Progressive liver damage and fibrosis in mice lacking Nrf2 and p65/RelA in 
hepatocytes  
To determine the long-term consequences of Nrf2 and p65/RelA deletion in 
hepatocytes, we analyzed mice at 6 months of age. At this age, AlbCre_Nrf2ko 
and AlbCre_p65/Nrf2ko mice still showed a reduced liver-to-body weight ratio 
(Fig. 3A). There was only a minor increase in serum AST activity in the double 
knockout mice (Fig. 3B). The number of TUNEL-positive apoptotic cells was 
increased in AlbCre_p65 and AlbCre_p65/Nrf2ko mice (Fig. 3C). 
Histopathological analysis of H&E stained liver sections revealed mild liver 
damage in AlbCre_p65ko and AlbCre_Nrf2ko mice and more severe damage 
combined with focal accumulation of inflammatory cells in AlbCre_p65/Nrf2ko 
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mice and the presence of fibrotic areas (Fig. 3D). This was confirmed by Sirius 
Red staining of collagen and histomorphometric quantification of the fibrotic 
areas (Fig. 3E). Immunohistochemical stainings for Ly6G (neutrophils), CD3 
(T cells), CD68 (macrophages) and B220 (B cells) and subsequent quantification 
of the different immune cells revealed an increase in B and T lymphocytes in 
AlbCre_p65/Nrf2ko mice at this time point (Fig. 3F). 
 
Formation of hepatocellular adenoma-like tumors in aged female mice lacking 
Nrf2 and p65/RelA in hepatocytes 
At the age of 18 months, the reduction in liver-to-body weight ratio was not 
further aggravated in AlbCre_Nrf2ko and AlbCre_p65/Nrf2 ko mice (Fig.4A), but 
the overall liver damage had become more severe (Fig. 4B-G). AST activity in 
the serum of AlbCre_Nrf2ko and of AlbCre_p65/Nrf2ko was increased at this 
time point, although the difference was not statistically significant due to the 
rather high variation among animals (Fig. 4B). AlbCre_p65ko and in particular 
AlbCre_p65/Nrf2ko mice exhibited necrosis (Fig. 4C,D) and inflammation (Fig. 
4C,E,F) in the liver, and the number of Ly6G-positive cells was significantly 
increased in AlbCre_p65/Nrf2ko mice compared to the other genotypes (Fig. 4E). 
Finally, fibrotic tissue was present (Fig. 4G).  
Most interestingly, tumors were detected in 4 out of 11 female mice, but in none 
of the 13 male mice that we analyzed (* p = 0.0311) (Fig. 5A). Histopathological 
analysis of these tumors revealed strong similarities with the inflammatory 
  
  Köhler et al. 
 16
subtype of human hepatocellular adenoma (iHCA) (Fig. 5B). This was confirmed 
by immunohistochemical staining for markers that distinguish between different 
HCA subtypes [22,23]. Like human iHCA (Fig. 5B, upper panels), the mouse 
tumors showed dilated, teleangiectasia-like sinusoids as highlighted by staining 
with a collagen IV antibody. Staining with a cytokeratin antibody that detects bile 
ducts confirmed that tumors were devoid of bile ducts/portal tracts (Fig.5B, 
middle panel). Both the human and the mouse tumors revealed only few 
proliferating tumor cells as revealed by Ki-67 staining, whereas large numbers of 
proliferating inflammatory cells were present. Furthermore, the tumor cells were 
positive for phosphorylated STAT3 (p-STAT3), indicative of active Jak/Stat 
signaling. In contrast to the human situation, where mutations (most likely 
somatic mutations) are restricted to the tumors, p-STAT3 staining was also seen 
in the non-tumorigenic liver of AlbCre_p65/Nrf2ko mice. This is likely due to the 
fact that all hepatocytes are deficient for Nrf2 and p65. Additional characteristics 
of human iHCA were seen in the mouse tumors, including (i) no loss of liver fatty 
acid binding protein (L-FABP), (ii) lack of nuclear β-catenin, (iii) lack of 
overexpression of the β-catenin target glutamine synthase (Fig. 5B, lower panel), 
and (iv) strong staining for serum amyloid A1 (SAA1) (Supplementary Figure S1). 
We next stained human iHCAs with antibodies against (activated) p-NRF2 and/or 
p65. Consistent with the situation in the mouse tumors, iHCAs were mostly 
negative for p-NRF2, with the exception of very rare positive hepatocytes mostly 
at the tumor border and around pseudo-portal tracts, whereas widespread 
nuclear p-NRF2 reactivity was detectable in the peritumoral tissue, including in 
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stromal cells, in particular immune cells, and in proliferating bile ducts (Fig. 6A). 
A similar result was obtained for NF-κB/p65: There was a strong staining in 
peritumoral cells, including immune cells, whereas the iHCA tumor cells were 
negative for nuclear p65 (Fig. 6B). Taken together, these results demonstrate 
that a deficiency in activated NF-κB/p65 and NRF2 is also a hallmark of human 
iHCA.  
 
Loss of p65 does not affect the expression of Nrf2 target genes involved in ROS 
defense 
The progressive liver damage that we observed in the AlbCre_p65/Nrf2ko mice, 
but not in the single knockout mice, suggested that both transcription factors 
have partially redundant cytoprotective functions in the liver. To assess potential 
collaborative roles in the antioxidant defense, we first analyzed the levels of 
carbonylated proteins as a parameter for ROS-induced cell damage. Oxyblot 
analyses showed that several carbonylated proteins were present at higher 
levels in AlbCre_Nrf2ko compared to AlbCre and AlbCre_p65ko mice, but 
additional loss of p65/RelA did not enhance this effect (Supplementary Fig. S2). 
Consistent with this finding, several Nrf2 target genes involved in the cellular 
antioxidant defense system were expressed at lower levels in Nrf2 knockout mice 
compared to wild-type controls, but their expression was not further reduced in 
the absence of p65. These include the genes encoding Nqo1 (Nqo1), glutathione 
S-transferase A2 (Gsta2), the glutathione biosynthesis enzyme glutamate 
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cysteine ligase catalytic subunit (Gclc), and the ROS-detoxifying enzyme 
peroxiredoxin 1 (Prdx1) (Fig. 7). Furthermore, there was no additive effect of Nrf2 
and p65 deficiency on the expression of aldehyde oxidase 1, carbonyl reductase 
3, peroxiredoxin 6 and epoxide hydrolase 1 (data not shown). The only exception 
was sulfiredoxin 1 (Srxn1), which was further repressed in the absence of p65 
(Fig. 7). Overall, this finding suggests that Nrf2 and NF-κB regulate different 
genes in the liver and that the combined alteration in the expression of these 
different target genes leads to the observed liver pathology. 
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Discussion 
We provide genetic evidence for an important collaborative function of Nrf2 and 
NF-κB in the control of liver homeostasis. While the absence of either Nrf2 or 
p65/RelA had no or only minor effects on liver morphology and function, 
simultaneous loss of both transcription factors caused progressive inflammation, 
followed by fibrosis and development of tumors resembling human iHCA.  
It has previously been shown that Nrf2 affects NF-κB activity and vice versa. For 
example, Nrf2 activating compounds attenuated NF-κB activation in response to 
lipopolysaccharide [24] or carbon tetrachloride [25]. Furthermore, activation of 
Nrf2 by phenethyl isothiocyanate or sulforaphane inhibited phosphorylation of the 
inhibitor of NF-κB and subsequent nuclear translocation of p65, thereby inhibiting 
NF-κB signaling [26]. However, off-target effects of the Nrf2 activating 
compounds could not be excluded in these experiments. Though, studies with 
Nrf2 knockout mice also argue for an effect of Nrf2 on NF-κB activity. Thus, Nrf2 
ablation accelerated NF-κB mediated pro-inflammatory reactions [27], and Nrf2 
deletion enhanced NF-κB DNA binding in the liver after PH [7]. However, direct 
evidence for a functional interplay of Nrf2 and NF-κB in vivo was still missing. 
The results obtained in the present study therefore provide the first genetic 
evidence for this cross-talk in the liver. 
Consistent with our previous findings [7], a reduction of the cellular antioxidant 
defense capacity was observed in the liver of Nrf2 knockout mice as reflected by 
the increase in oxidized proteins and the reduced expression of various genes 
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with a direct or indirect role in ROS defense. However, this was not further 
aggravated by the loss of p65, suggesting that Nrf2 and p65 regulate different 
sets of genes with different roles in cytoprotection. Of particular interest in this 
context are genes encoding anti-apoptotic proteins, which are under control of 
NF-κB [28-33]. Interestingly, lack of p65 in hepatocytes sensitized hepatocytes to 
pro-apoptotic stimuli such as TNF-α or lipopolysaccharide [13,15], and this was 
inhibited by administration of antioxidants [15]. Thus, in the absence of Nrf2 and 
the associated increase in ROS levels, the pro-apoptotic effect of a loss of NF-κB 
could be aggravated. Consistent with this assumption, Nrf2 deficiency enhanced 
the sensitivity of hepatocytes to TNF-α induced apoptosis in vivo, resulting in the 
development of severe hepatitis [34]. Since significant apoptosis was only 
detected in aged AlbCre_p65/Nrf2ko mice, this possibility, however, is unlikely 
the primary cause for the spontaneous inflammation seen in young 
AlbCre_p65/Nrf2ko mice. The latter may involve non cell-autonomous 
mechanisms, such as induction of cytokines or other mediators in the absence of 
Nrf2 and NF-κB in hepatocytes, which initiate an inflammatory response. The 
additional loss of Nrf2 in non-parenchymal cells may further aggravate such an 
effect, and future studies using mice lacking Nrf2 and p65 only in hepatocytes will 
clarify this issue. 
The onset of inflammation in AlbCre_p65/Nrf2ko mice was first reflected by an 
increase in intrahepatic lymphocytes. This may suggest that hepatocytes 
deficient in Nrf2 and NF-κB/p65 are recognized by cells of the adaptive immune 
system, possibly due to presentation of as yet uncharacterized antigens. At later 
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stages, a significant increase in neutrophils and macrophages was also 
observed. Similar to chronic hepatitis in humans, the inflammatory response was 
followed by the development of liver fibrosis. In the future, it will therefore be 
interesting to determine the expression/activation of both NRF2 and NF-κB in 
fibrotic and cirrhotic human liver.  
Interestingly, a significant fraction of aged female, but not of male 
AlbCre_p65/Nrf2ko mice developed lesions that share various features with 
human iHCA, a rare benign primary liver cell tumor [35]. HCAs comprise a 
heterogenous group of tumors characterized by specific phenotypic and genetic 
alterations. Currently, they are divided into 4 subtypes: (a) iHCA, (b) HCAs with 
mutations in the gene encoding hepatocyte nuclear factor 1α, (c) HCAs with 
mutations in the β-catenin gene and (d) “unclassified” HCA without known 
genetic alterations [36]. The tumors in our mutant mice showed various 
similarities to human iHCA at the histological and immunohistochemical level. 
iHCA accounts for 30-40% of all HCAs and occurs predominantly in young 
women, who use oral contraceptives with high estrogen content and often exhibit 
a systemic inflammatory condition [37]. Therefore, the exclusive detection of the 
iHCA-like lesions in female mice is of particular interest and raises the intriguing 
possibility that estrogens may affect the response of liver cells to Nrf2 and NF-κB 
deficiency.  
Approximately 90% of iHCAs in humans are characterized by somatic activating 
mutations in the gene encoding interleukin-6 (IL-6) signal transducer/gp130, or in 
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additional genes that result in activation of STAT3 in an IL-6-independent manner 
[38,39,40]. iHCAs also display overexpression of CCL20, accounting for the 
recruitment of inflammatory cells to the lesions [39,41]. It is as yet unclear if 
these mutations are causative or only required for the progression of the tumors. 
A role of NRF2 and NF-κB in the pathogenesis of iHCA has as yet not been 
demonstrated, and mutations in these genes have not been detected in human 
iHCA [40]. However, our finding that simultaneous deficiency in Nrf2 and p65 in 
murine hepatocytes is sufficient to activate Stat3 and to initiate the development 
of liver tumors reminiscent of human iHCA, raised the question of a possible 
deficiency in one or both of these transcriptions factors in human iHCA. Indeed, 
the tumor cells of five analyzed human HCAs did not show immunoreactivity for 
nuclear p-NRF2 and NF-κB/p65, suggesting that a deficiency in the expression 
and/or activation of these important cytoprotective transcription factors is also a 
hallmark of human iHCA and may contribute to the pathogenesis of this type of 
tumor.  
Although benign, iHCAs can become life-threatening due to bleeding, which 
occurs in 30% of these tumors. Furthermore, up to 10% of iHCA, in particular 
those harboring β-catenin mutations, progress to hepatocellular carcinomas 
[22,42]. Thus, identification of novel strategies for the prevention and/or 
treatment of HCA is of strong medical interest, and the findings described in this 
study suggest that activation of NRF2 and/or NF-κB could be a promising 
strategy in patients diagnosed with HCA or in high-risk female and/or obese 
patients. 
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Legends to Figures 
 
Figure 1. Verification of the loss of p65/RelA and Nrf2 in hepatocytes. (A,B) 
RNA from total liver of AlbCre, AlbCre_p65ko, AlbCre_Nrf2ko and 
AlbCre_p65/Nrf2ko mice was analyzed by qRT-PCR for expression of p65 (A) 
and Nrf2 (B, left panel) relative to 18s RNA (N = 6 per genotype). Error bars 
represent mean ± s.d. P-values are two-tailed and were calculated using 2-way 
ANOVA. The tabular results are shown below each bar graph. Statistically 
significant differences are highlighted in bold. Nrf2 and 18sRNA PCR products 
were loaded on an agarose gel (B, right panel). (C) Total liver lysates (30 µg 
protein) were analyzed by immunoblotting for p65 and GAPDH (loading control). 
(D) Liver sections were analyzed by immunofluorescence for p65 (red); nuclei 
were counterstained with DAPI (blue). Note the remaining p65 staining in blood 
vessels of AlbCre_p65ko mice. Bar: 50 µm. 
 
Figure 2. Lack of p65 and Nrf2 in hepatocytes induces focal liver damage. 
Mice were analyzed at the age of 2 months. (A) Liver-to-body weight ratio in 
AlbCre, AlbCre_p65ko, AlbCre_Nrf2ko and AlbCre_p65/Nrf2ko mice (N = 10 per 
genotype). (B) AST activity in the serum (N = 4). (C) TUNEL-positive (apoptotic 
cells) in liver sections (N = 5 per genotype). (D) Representative H&E-stained liver 
sections (out of 10 mice per genotype). Bars: 100 µm. (E) Numbers of Ly6G- and 
CD3-positive cells per area in liver sections (N = 5 per genotype). Error bars 
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represent mean ± s.d. p-values are two-tailed and were calculated using a 
regular 2-way ANOVA. The tabular results are shown below each bar graph. 
  
Figure 3. Progressive inflammation and fibrosis in AlbCre_p65/Nrf2ko mice. 
Mice were analyzed at the age of 6 months. (A) Liver-to-body weight ratio 
(N = 10 per genotype). (B) Serum activity of AST (N = 4 per genotype). (C) 
TUNEL-positive (apoptotic) cells in liver sections (N = 5 per genotype). (D,E) 
Representative H&E- or Sirius Red-stained liver sections from mice of all four 
genotypes. Bars: 100 µm. Bar graph in (E) shows area of fibrotic tissue as 
determined by histomorphometrical analysis of Sirius Red-stained sections 
(N = 5). (F) Ly-6G-, CD3-, CD68-, or B220-positive cells (N = 5 per genotype). 
Error bars represent mean ± s.d. p-values are two-tailed and were calculated 
using 2-way ANOVA. The tabular results are shown below each bar graph. 
Statistically significant differences are highlighted in bold. 
 
Figure 4. Severe liver damage and fibrosis in aged p65/Nrf2-deficient mice.  
Mice were analyzed at the age of 18 months. (A) Liver-to-body weight ratios 
(N = 10 per genotype). (B) Serum activity of AST (N = 4 per genotype). (C) 
Representative liver sections from mice of all genotypes stained with H&E. Bars: 
100 µm. (D) Histological scoring of necrosis using H&E-stained liver sections, 
performed blinded by a liver pathologist. Scatter plot shows data points from 
individual mice. Score 0: no necrosis; Score 1: spotty necrosis; Score 2: 
confluent necrosis. (E) Numbers of Ly6G-positive cells in liver sections 
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determined by immunohistochemistry (N = 4 per genotype). (F) Inflammation 
scoring using H&E-stained liver sections, performed blinded by a liver 
pathologist. Score 0: no inflammation; Score 1: mild inflammation; Score 2: 
moderate inflammation; Score 3: strong inflammation. (G) Area of fibrotic tissue 
as determined by histomorphometrical analysis of Sirius Red-stained sections 
(N = 4). Error bars represent mean ± s.d. p-values are two-tailed and were 
calculated using 2-way ANOVA. The tabular results are shown below each bar 
graph. Statistically significant differences are highlighted in bold. 
  
Figure 5. Aged female p65/Nrf2-deficient mice develop tumors resembling 
human iHCA. (A) Adenoma incidence in aged AlbCre_p65/Nrf2ko mice. Note 
the statistically significant difference in tumor formation between male and female 
mice according to Fisher’s exact test. (B) Representative sections from a human 
iHCA adjacent to non-tumorigenic liver (upper row) and from a mouse lesion 
adjacent to non-tumorigenic liver, stained with H&E (black-filled arrowheads 
indicate lymphocyte infiltrates; white-filled arrowheads indicate dilated, 
teleangiectasia-like sinusoids) or immunostained for collagen IV, cytokeratin 7 
(human) or pan-cytokeratin (mouse), Ki-67, p-STAT3, L-FABP, β-catenin (note 
the positive membrane staining, but the lack of nuclear staining) and glutamine 
synthase. Bars: 100 µm; 50 µm in inserts.  
 
Fig. 6 Lack of nuclear p-NRF2 and NF-κB/p65 in the tumor cells of human 
iHCA. Representative sections from a human iHCA (T) adjacent to non-tumorous 
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liver (PT) immunostained with antibodies against p-NRF2 (A) or p65 (B). Higher 
magnifications of tumor cells or peri-tumoral tissue are shown in the left or right 
panels, respectively. Black arrowheads: bile ducts; white arrowheads: 
inflammatory cells.  Bars: 200 µm (middle panel) or 100 µm (left and right 
panels).  
 
Figure 7. Effect of Nrf2 and/or p65 deficiency on expression of Nrf2 target 
genes involved in ROS defense. RNA from total liver of 8 week-old mice was 
analyzed by qRT-PCR for the expression of the Nrf2 target genes Srxn, Nqo1, 
Gsta2, Gclc and Prdx1 relative to 18s rRNA (N = 3-5 per genotype). Error bars 
represent mean ± s.d. p-values are two-tailed and were calculated using 2-way 
ANOVA. The tabular results are shown below each bar graph. Statistically 
significant differences are highlighted in bold. 
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